Botanix Pharmaceuticals Limited BXPHF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 523.83% | 640.80% | 945.18% | 556.73% | 170.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 523.83% | 640.80% | 945.18% | 556.73% | 170.50% |
| Cost of Revenue | 304.11% | 207.50% | 116.12% | 59.75% | 1.00% |
| Gross Profit | 947.56% | 52,884.47% | 828.88% | 544.81% | 220.98% |
| SG&A Expenses | 10.27% | 54.94% | 148.90% | 245.83% | 557.26% |
| Depreciation & Amortization | 7.20% | 37.27% | 92.52% | 252.51% | 2,971.91% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.66% | 63.41% | 144.34% | 222.21% | 441.60% |
| Operating Income | 11.86% | -27.17% | -103.46% | -196.99% | -481.75% |
| Income Before Tax | 14.70% | -28.66% | -119.49% | -217.72% | -510.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.70% | -28.66% | -119.49% | -217.72% | -510.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.70% | -28.66% | -119.49% | -217.72% | -510.81% |
| EBIT | 11.86% | -27.17% | -103.46% | -196.99% | -481.75% |
| EBITDA | 12.40% | -26.87% | -103.79% | -195.67% | -468.77% |
| EPS Basic | 27.00% | -16.14% | -101.35% | -183.81% | -400.00% |
| Normalized Basic EPS | 26.60% | -16.43% | -101.08% | -183.33% | -394.74% |
| EPS Diluted | 27.00% | -16.14% | -101.35% | -183.81% | -400.00% |
| Normalized Diluted EPS | 26.60% | -16.43% | -101.08% | -183.33% | -394.74% |
| Average Basic Shares Outstanding | 17.34% | 15.50% | 13.48% | 17.90% | 22.87% |
| Average Diluted Shares Outstanding | 17.34% | 15.50% | 13.48% | 17.90% | 22.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |